NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

MOLN Shareholders Click Here: https://www.zlk.com/pslra-1/molecular-partners-class-action-loss-submission-form?prid=30865&wire=1
MF Shareholders Click Here: https://www.zlk.com/pslra-1/missfresh-limited-loss-submission-form?prid=30865&wire=1
YQ Shareholders Click Here: https://www.zlk.com/pslra-1/17edtech-loss-submission-form?prid=30865&wire=1

* ADDITIONAL INFORMATION BELOW *

Molecular Partners AG (NASDAQ:MOLN)

This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Molecular Partners American Depositary Shares pursuant and/or traceable to certain documents issued in connection with the Company's initial public offering conducted on or about June 16, 2021; and/or (b) Molecular Partners securities between June 16, 2021, and April 26, 2022.
Lead Plaintiff Deadline : September 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/molecular-partners-class-action-loss-submission-form?prid=30865&wire=1

According to the filed complaint, (i) the Company's product, ensovibep, was less effective at treating COVID-19 than defendants had led investors to believe; that (ii) accordingly, the the U.S. Food and Drug Administration ('FDA') was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization ('EUA'); (iii) waning global rates of COVID-19 significantly reduced the Company's chances of securing EUA for ensovibep; (iv) another of the Company's product candidates, MP0310, was less attractive to Molecular Partners' collaborator, Amgen, than defendants had led investors to believe; (v) accordingly, there was a significant likelihood that Amgen would return to global rights of MP0310 to Molecular Partners; (vi) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (vii) as a result, documents issues in connection with the Company's initial public offer and defendants' public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

Missfresh Limited (NASDAQ:MF)

This lawsuit is on behalf of persons who purchased or otherwise acquired Missfresh securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Missfresh's June 2021 initial public offering.
Lead Plaintiff Deadline : September 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/missfresh-limited-loss-submission-form?prid=30865&wire=1

According to the filed complaint, (1) Missfresh provided false financial figures in its registration statement
and related prospectus issued in connection with the Company's June 2021 initial public offering; (2) Missfresh would need to amend its financial figures; (3) Missfresh, among other things, had lesser net revenues for the quarter ended March 31, 2021; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared.

17 Education & Technology Group Inc. (NASDAQ:YQ)

This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded 17EdTech securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with 17EdTech's December 2020 initial public offering.
Lead Plaintiff Deadline : September 19, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/17edtech-loss-submission-form?prid=30865&wire=1

According to the filed complaint, (1) 17EdTech's K-12 Academic AST Services would end less than a year after the Company's initial public offering; (2) as part of its ongoing regulatory efforts, Chinese authorities would imminently curtail and/or end 17EdTech's core business; and (3) as a result, defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP